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The anticancer mechanism of ibuprofen atau indomethacin in 
colorectal cancer cells 
 
      Abstract 
 
Ibuprofen and indomethacin are among the frequently studied 
non-steroidal anti-inflammatory drugs (NSAIDs) for their anticancer 
activities. Besides being non-selective cyclooxygenase-2 (COX-2) 
inhibitors, both NSAIDs are also direct ligands for peroxisome 
proliferators-activated receptor-gamma (PPARγ). However, the precise 
mechanism(s) of action whereby both NSAIDs exert their anticancer 
effect remain unclear. In this study, we investigated the effects of both 
NSAIDs in constitutively COX-2-expressing (HCA-7 and HT29) and non-
constitutively COX-2-expressing (HCT116) cell lines. Our initial aim of the 
study was to determine the NSAID growth inhibitory effect as well as the 
effective concentration to inhibit 50% of cell growth (EC50) of each NSAID 
in each cell line using lactate dehydrogenase (LDH) release assay. The 
apoptosis mechanism was then investigated using M30 CytoDEATH 
assay prior to flow cytometry analysis. The apoptotic-related proteins 
such as caspase-8, -9, -3 and -7 were also investigated using Western 
blot analysis, whereas the modulation of mRNA expression of relevant 
molecular targets such as COX-2, c-myc, β-catenin, TCF-4 and PPAR 
subtypes (α, δ, γ1 and γ2) mRNA was quantified using Real-time PCR 
analysis. Our results demonstrated that both NSAIDs produced 
remarkable inhibition on the growth of all three cell lines tested. The 
iii 
inhibitory effect occurred in a concentration- and time-dependent 
manner, with indomethacin (EC50 value >100 µM) being more potent 
compared to ibuprofen (EC50 value >1000 µM). Furthermore, the ability 
of both NSAIDs in inhibiting the growth of cells is likely not to be 
associated with COX-2 expression. The evidence from M30 CytoDEATH 
assay suggested that the major mode of cell death caused by both 
NSAIDs was caspase-dependent apoptosis. This evidence was further 
supported by Western blot analysis which indicated that the induction 
occurred via caspase-9-dependent pathway, whereas the Real-time PCR 
analysis showed that both NSAIDs appear to modulate gene expression 
via a variety of different molecular targets in COX-2-dependent and/or 
independent pathway(s) depending on the colorectal cancer (CRC) cell 
type. However, alteration of TCF-4 and PPARγ1 mRNA expression are 
likely essential for both NSAIDs to induce apoptosis. Thus, Wnt and 
PPARγ signaling pathways may be involved in mediating the apoptosis 
induced by both NSAIDs in CRC cells. In addition, PPARδ is found to be 
another essential molecular target for indomethacin-induced CRC cell 
apoptosis. In conclusion, our study may provide additional information 
and evidence of the various mechanisms and actions of NSAIDs in 
human CRC cells which may be useful in selecting effective apoptotic 
drugs against specific CRC types. As we and others have shown, both 
NSAIDs have anti-CRC activities and are potential anti-CRC agents. 
Further studies on the effect of both NSAIDs on CRC cells remain 
important, as they may be developed as chemotherapeutic agents for 
human CRC.  
iii 
Antikanser mekanisme ibuprofen atau indomethacin dalam sel 
kanser kolorektal 
 
       Abstrak 
 
Ibuprofen dan indometasin adalah antara drug antiinflamatori 
bukan steroid (NSAIDs) yang kerap dikaji untuk aktiviti-aktiviti anti 
kansernya. Selain daripada perencat siklooksigenase-2 (COX-2) bukan 
pilihan, kedua-dua NSAIDs ini adalah ligan langsung untuk reseptor-
gama pengaktif proliferators peroksimase (PPARγ). 
Walaubagaimanapun, tindakan mekanisme atau mekanisme-mekanisme 
yang tepat yang mana kedua-dua NSAIDs mengenakan kesan anti 
kanser masih lagi tidak jelas. Kajian ini menyiasat kesan garis sel pada 
kedua-dua NSAIDs dalam sebahagian ekspresi COX-2 (HCA-7 dan 
HT29) dan bukan pada sebahagian ekspresi COX-2. Pada awalnya, 
kajian ini dijalankan untuk menentukan kesan perencatan pertumbuhan 
NSAIDs dan juga kepekatan (concentration) yang berkesan untuk 
merencat 50% daripada sel pertumbuhan (EC50) pada setiap NSAIDs di 
setiap garis sel menggunakan dehidrogenase laktat  (LDH) yang 
mengeluarkan assay. Mekanisme apoptosis kemudiannya disiasat 
menggunakan assay M30 CytoDEATH sebelum analisis aliran sitometri 
dijalankan. Protein-protein berkaitan apoptotic seperti caspase-8, -9, -3 
dan -7 juga telah disiasat menggunakan analisis blot  Western, manakala 
modulasi ekspresi mRNA untuk molekul sasaran yang berkaitan  seperti 
COX-2, c-myc,  β-catenin, TCF-4 dan subjenis-subjenis PPAR mRNA (α, 
iii 
δ, γ1 dan γ2) dikuantitikan menggunakan analisis PCR masa-sebenar 
(REAL-time). Keputusan menunjukkan bahawa kedua-dua NSAIDs 
menghasilkan perencatan yang luar biasa pada pertumbuhan ketiga-tiga 
garis sel. Indometasin (nilai EC50  > 100 µM) adalah lebih kuat jika 
dibandingkan dengan ibuprofen (nilai EC50 > 1000 µM). Tambahan pula 
kebolehan kedua-dua NSAIDs dalam merencat pertumbuhan sel-sel 
mungkin tidak akan dikaitkan dengan ekspresi COX-2. Bukti dari assay 
M30 CytoDEATH mengusulkan bahawa mod utama kematian sel adalah 
disebabkan kedua-dua NSAIDs adalah apoptosis yang bergantung pada 
caspase.  Bukti ini seterusnya disokong oleh analisis blot Western yang 
menunjukkan bahawa cetusan berlaku melalui laluan yang bergantung 
pada caspase-9, manakala analisis PCR masa-sebenar (REAL-time) 
menunjukkan bahawa kedua-dua NSAIDs kelihatan memodulat ekspresi 
gen melalui  pelbagai sasaran molekul yang berbeza dalam laluan atau 
laluan-laluan yang bergantung atau tidak bergantung pada COX-2 dan 
ini bergantung kepada jenis sel kanser kolorektal (CRC). 
Walaubagaimanapun perubahan pada TCF-4 dan  ekspresi mRNA 
PPARγ adalah agak penting kepada kedua-dua NSAIDs untuk mencetus 
apoptosis. Oleh itu laluan-laluan isyarat Wnt dan PPARγ mungkin terlibat 
sebagai perantara apoptosis yang dicetus oleh kedua-dua NSAIDs 
dalam sel-sel CRC. Sebagai tambahan, PPARδ pula didapati sebagai 
satu lagi sasaran molekul yang penting untuk apoptosis sel CRC 
cetusan-indometasin. Kesimpulannya, kajian ini mungkin dapat memberi 
maklumat tambahan dan bukti pelbagai mekasisme-mekanisme dan 
tindakan-tindakan NSAIDs dalam sel CRC manusia, yang mungkin 
iii 
berguna untuk memilih drug apoptotic yang berkesan terhadap jenis 
CRC yang spesifik. Seperti yang telah kami dan penyelidik-penyelidik 
lain telah tunjukkan, kedua-dua NSAIDs mempunyai aktiviti-aktiviti anti-
CRC dan berpotensi sebagai agen anti-CRC. Kajian-kajian lanjut 
mengenai kesan kedua-dua NSAIDs pada sel-sel CRC tetap penting 
kerana mereka  boleh dibangunkan sebagai agen kemoterapeutik untuk 
CRC manusia. 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
1.1 Introduction of NSAIDs 
  
 Non-steroidal anti-inflammatory drugs (NSAIDs) were first 
introduced in the 1900s, and have subsequently been widely used to 
treat inflammation, mild-to-moderate pain and fever (Vane and Botting, 
1998). Although they have been used for more than two decades and 
their safety has constantly been reviewed, they have only recently been 
proposed as anti-cancer agents (Vane and Botting, 1998). NSAIDs work 
mainly by inhibiting cyclooxygenase (COX) and preventing the formation 
of prostaglandins (PGs) (Smith and Goh, 1996; Badawi et al., 2000; Han 
et al., 2001). There are two isoforms of COX which are known as COX-1 
and COX-2 (Sheng et al., 1997; Badawi et al., 2000). COX-1 is 
continuously secreted within the stomach and duodenum where it helps 
maintain healthy stomach lining, normal kidney function and the clotting 
action of blood platelets (Sheng et al., 1997). In contrast, the COX-2 
enzyme is primarily found at sites of inflammation (Sheng et al., 1997). It 
is induced by inflammatory stimuli such as interleukin-1, and is 
suppressed by glucocorticoids (Sheng et al., 1997).  
 
Blocking of COX-2 is effective in relieving pain and inflammation, 
whereas inhibiting of COX-1 often produces unacceptable 
gastrointestinal side effects such as diarrhea, bloating, heartburn, 
stomach upset and ulcers (Vane and Botting, 1998). Various 
conventional NSAIDs such as aspirin, diclofenac, ibuprofen, 
indomethacin, naprosyn and piroxicam are being used as anti-cancer 
 
agents (Soh and Weinstein, 2003). These NSAIDs inhibit both COX-1 
and COX-2 to differing degrees in terms of the relative specificity ratio 
(IC50; Figure 1.1) (Mitchell et al., 1994; Bishop-Bailey et al., 1997; 
Bishop-Bailey and Warner, 2003). 
 
 The lower ratio value reflects the more potent activity of NSAIDs 
against COX-2 inhibition. Thus, SC58125 (celecoxib derivative) and 
celecoxib appear to be more selectively involved in COX-2 inhibition 
activity than naproxen and flurbiprofen (Figure 1.1). Besides indicating 
the selectivity of NSAIDs in COX-2 inhibition, ratio IC50 adequately 
explains the variations in the side effects of NSAIDs at their anti-
inflammatory doses (Vane and Botting, 1998). Selective COX-2 inhibitors 
such as celecoxib which have higher potency on COX-2 inhibition activity 
will have potent anti-inflammatory activity with fewer side effects on the 
stomach and kidney (Henry, 2003; Langman, 2003; Wolfe, 2003), 
whereas non-selective COX-2 inhibitors such as aspirin, piroxicam, 
ibuprofen and indomethacin which have a higher potency against COX-1 
than against COX-2 inhibition activity, were found to produce high 
gastrointestinal toxicity and cause the most damage to the stomach at 
inflammatory doses (Lanza et al., 1989; Rodriguez et al., 1994). 
 
 
 
 
 
1.2 The non-selective COX inhibitors 
 
The ability of NSAIDs to decrease the COX-1/COX-2 expression 
has allowed consideration of NSAIDs as potential anti-cancer agents for 
cancer treatment including human colorectal cancer (CRC) treatment 
(Vane and Botting, 1998). COX-2 expression has been shown to be up-
regulated in human CRC when compared with normal adjacent colonic 
mucosa (Na and Surh, 2003). Inhibition of the COX-2 expression is 
important because over expression of COX-2 provides tumor cells with 
growth and survival advantages including resistance to apoptosis, and 
increased invasiveness or angiogenesis (Mohammed et al., 1999; 
Cianchi et al., 2001; Yamada et al., 2001; Na and Surh, 2003).  
 
Thus, targeting the inhibition of COX-2 is regarded as an affective 
and promising strategy for cancer prevention and treatment (Han et al., 
2001; Na and Surh, 2003). Indeed, the expression of COX-2 is 
stimulated by growth factors and tumor promoters, and it is often 
selectively expressed in tumors cells including CRC cells (Eberhart et al., 
1994; Sano et al., 1995; Han et al., 2001). Thus, the expression of COX-
2 is believe that plays an important role in cancer, and is often correlated 
with tumorigenesis. This correlation was supported by the finding that in 
two mutated adenomatous polyposis coli (APC) background mice where 
the COX-2-/- mice developed fewer intestinal polyps than the COX-2+/+ 
mice (Oshima et al., 1996; Han et al., 2001).  
 
 
Many epidemiologic and clinical studies have revealed that regular 
ingestion of NSAIDs such as aspirin, sulindac and indomethacin can 
reduce the risk of developing several malignant tumors including CRC 
(Giardiello et al., 1995; Giovannucci et al., 1995; Boolbol et al., 1996). 
Based on the evidences above, it is logical to choose a selective COX-2 
inhibitor that is as effective as non-selective inhibitors and could prevent 
PGs formation in inflamed areas without interfering with the activity in 
stomach and kidney (Vane and Botting, 1998). However, COX-2 appears 
to have multiple functions and has been shown to be important in 
ovulation and vasoprotection, and is essential for normal kidney 
development (Dahl, 1999). Indeed, both COX-1 and COX-2 are 
expressed in inflamed joints, so it is important that mixed COX inhibition 
is required for the maximal anti-inflammatory effects (Dahl, 1999).  
 
 
1.3 Evaluation of NSAIDs as PPARγ ligands 
 
Non-selective COX inhibitors are regarded as effective and 
promising anti-cancer agents for cancer prevention or treatment. 
However, the fact that NSAIDs retain the anti-proliferative activity in a 
variety of cells that do not express COX-2 would argue against the 
relevance of COX-2 inhibition as a target for NSAIDs in cancer cells 
(Hanif et al., 1996; Zhang et al., 1999; Chapple et al., 2000; Smith et al., 
2000; Han et al., 2001; Hull et al., 2003). Indeed, the concentration of 
NSAIDs required to induce cell death was several orders of magnitude 
 
higher than that required to inhibit the activity of COX (Mitchell et al., 
1993; Han et al., 2001). For example, the IC50 ratio of indomethacin to 
inhibit COX-1 and COX-2 in intact cells were reported to be 28 nM and 
1.7 µM, respectively (Mitchell et al., 1993), whereas the concentration of 
indomethacin used to induce cell death in the same cells was 500 µM 
(Zhang et al., 1999). Therefore, the anti-proliferative activity of NSAIDs 
would seem to occur via COX-independent mechanisms (Hull et al., 
2003; Soh and Weinstein, 2003). 
 
One possible mechanism was suggested to be via the peroxisome 
proliferators-activated receptor-gamma (PPARγ), a ligand-activated 
transcription factor pathway (Smith et al., 2000; Hull et al., 2003; Soh and 
Weinstein, 2003). According to Lehmann et al. (1997), several NSAIDs 
including ibuprofen and indomethacin, can interact directly and 
specifically bind with PPARγ ligand binding domain (LBD). Upon ligand 
binding, PPARγ becomes activated and heterodimerises with retinoid X 
receptor (RXR) (Figure 1.2) (Boitier et al., 2003). The co-repressors will 
then dissociate from the complex which leads to an active PPARγ/RXR 
complex that binds to the gene regulatory sites on DNA termed PPAR 
response elements (PPRE). There is also evidence of the involvement of 
co-activator proteins that enhance the activity of the PPARγ/RXR 
complex. Binding of the PPARγ/RXR complex to PPRE increases the 
transcription of numerous genes including genes involve in 
tumorigenesis (Boitier et al., 2003). The ability of NSAIDs to bind to 
PPARγ has been previously assessed in a competition-binding assay 
 
using [3H] BRL49653 and bacterially expressed PPARγ LBD (Lehmann 
et al., 1997). Though not all NSAIDs activate PPARγ through direct 
interactions with the receptor, the fact that NSAIDs bind and thereby 
activate PPARγ activity, subsequently define them as the PPARγ ligands 
(Lehmann et al., 1997).  
 
Interestingly, ibuprofen and indomethacin used in this study are 
non-selective COX inhibitors and direct PPARγ ligands. Activation of 
PPARγ by ibuprofen and indomethacin was the strongest of any of the 
NSAIDs that were evaluated in CRC (Nixon et al., 2003). Furthermore, 
both NSAIDs may activate more than one PPAR subtypes. For example, 
ibuprofen activates PPARdelta (PPARδ)  and PPARγ (Kojo et al., 2003), 
whereas indomethacin shows agonistic activity for PPARalpha (PPARα) 
and PPARγ (Lehmann et al., 1997) or PPARγ alone based on two 
different studies  (Kojo et al., 2003). As dual ligands have been proven to 
be more effective at preventing colorectal carcinogenesis, ibuprofen and 
indomethacin are therefore potential anti-cancer agents for human CRC. 
 
 
1.4 The role of PPARγ ligands in cancer 
 
 The mechanisms of anti-cancer effect by the PPARγ ligands have, 
however, not been fully elucidated. In general, activation of PPARγ by its 
ligand is associated with cancer prevention (Brockman et al., 1998; 
Sarraf et al., 1998; Kitamura et al., 1999). The PPARγ ligands have anti-
 
proliferative and pro-differentiation effects in slowing the proliferation of 
tumor cells including breast (Elstner et al., 1998; Rubin et al., 2000), 
colon (Sarraf et al., 1998), prostate (Kubota et al., 1998; Hisatake et al., 
2000; Shappell et al., 2001), gastric (Takahashi et al., 1999) and 
pancreatic (Motomura et al., 2000) cancer cells.  
 
 In support of the former findings, the thiazolidinediones (TZD) 
group of PPARγ ligands has been shown to inhibit proliferation of breast, 
prostate and colon cells (Elstner et al., 1998; Kubota et al., 1998; Sarraf 
et al., 1998). In contrast, the ligands promote the development of colon 
tumors in transgenic mice in which one copy of the gene encoding the 
APC is knocked out, predisposing them to colon cancer (Lefebvre et al., 
1998). However, another study demonstrated that treatment of patients 
with liposarcomas with a PPARγ ligand results in anti-neoplastic pro-
differentiation which may decrease the proliferative rate of the cancer 
cells and slow the progression of the disease (Demetri et al., 1999). 
There are also observations that PPARγ ligands induce growth arrest 
and the synthesis of differentiation markers in human CRC cells 
(Kitamura et al., 1999). Furthermore, PPARγ ligands have been shown to 
be potent inhibitors of angiogenesis, a process necessary for solid-tumor 
growth and metastasis (Xin et al., 1999). Although much of the evidence 
suggests that activation of PPARγ by its ligands could promote the 
suppression of tumor growth and inhibit carcinogenesis, the precise 
mechanisms involved remain unclear.  
  
 
PPARγ ligands have been shown to exert their anti-cancer cell 
proliferation through the induction of apoptosis (Yang and Frucht, 2001; 
Clay et al., 2002). Although the precise role of PPARγ in cancer cells is 
still debatable, accumulating evidence has reported that PPARγ ligands 
inhibiting cancer cell growth via apoptosis (Yang and Frucht, 2001; Clay 
et al., 2002; Na and Surh, 2003). The apoptosis pathway is currently the 
key mechanism by which anti-cancer agents kill tumor cells. The ability of 
PPARγ ligands to decrease COX-2 expression and initiate apoptosis has 
made them to be considered as potential therapeutic agents for cancer 
treatment (Yang and Frucht, 2001; Debatin, 2004). Therefore, 
identification of the molecular pathways induced by PPARγ ligands will 
be of both basic and clinical importance. 
 
 
1.5 Apoptosis 
 
 Apoptosis, first reported in 1964, is also known as programmed 
cell death (Gewies, 2003). It is the physiological process by which 
unwanted cells are eliminated during development and other normal 
biological processes (Gewies, 2003). Moreover, cytotoxic T-lymphocytes 
(CTLs) kill virus-infected cells are also via the induction of apoptosis 
(Roberts, 2000). Currently, understanding of the apoptosis plays an 
important role in the study of physiological processes, particularly those 
involved in cancer research (Roberts, 2000). For example, the mutation 
of the p53 gene produces defective proteins that are often found in 
 
cancer cells which contribute to resistance to apoptosis (Debatin, 2004). 
Moreover, immunotherapy of tumors requires target cells with an 
apoptosis-sensitive phenotype (Debatin, 2004).  
 
Apoptosis is of major importance in the pathogenesis of several 
diseases including cancer, AIDS and neurological disorders such as 
Alzheimer’s and Parkinson’s diseases (Roberts, 2000). It is believed that 
defects in the apoptotic pathways represent hallmarks of tumorigenesis 
(Okada and Mak, 2004). Recent research on new cancer therapies has 
therefore focused on devising ways to overcome this resistance and to 
trigger apoptosis of cancer cells (Okada and Mak, 2004). 
 
 
1.6 Morphological features of necrosis and apoptosis 
 
 In the cell death process, necrosis occurs when cells are exposed 
to a serious physical or chemical insult (Gewies, 2003). The necrotic 
mode of cell death, in which cells suffer a major insult, results in a loss of 
membrane integrity, swelling and cell rupture (Figure 1.3). During 
necrosis, the cellular contents are released uncontrolled into the 
environment which results in damage to surrounding cells and a strong 
inflammatory response in the corresponding tissue (Gewies, 2003).  
 
In contrast to necrosis, apoptosis is characterised by typical 
morphological and biochemical hallmarks including cell shrinkage, 
 
nuclear DNA fragmentation and membrane blebbing (Debatin, 2004). 
The morphological changes such as cell shrinkage and deformation 
results in the cells loss of contact with neighboring cells and chromatin 
condensation (Figure 1.3). The chromatin is then localised at the nuclear 
membrane, the plasma membrane undergoes blebbing and finally the 
cell is fragmented into compact membrane-enclosed structures termed 
apoptotic bodies. The apoptotic bodies contain cytosol, condensed 
chromatin and organelles. They are removed from the tissue by 
phagocytosis or secondary necrosis without causing an inflammatory 
response. 
 
 
1.7 The putative mechanisms of PPARγ ligand-induced apoptosis 
 
As described above, treatment with PPARγ ligands has been 
widely implicated to reduce the cancer cell growth rate and induce cell 
terminal differentiation of a number of human cancers including CRC via 
induction of apoptosis (Yang and Frucht, 2001; Boitier et al., 2003). 
According to Goke et al. (2000), the induction of apoptosis by PPARγ 
ligands is increased by co-stimulation with tumor necrosis factor (TNF)-
related apoptosis-inducing ligand (TRAIL), a member of the TNF family. 
Furthermore, inhibition of cell growth observed in human breast cancer 
cells treated in vitro with PPARγ ligands is accompanied with a marked 
increase in apoptosis and a profound decrease of Bcl-2 gene expression 
(Elstner et al., 1998). In addition, troglitazone-induced apoptosis has 
 
been demonstrated to be associated with caspase-dependent and -
independent mechanisms (Yoshizawa et al., 2002). More importantly, 
Yoshida et al. (2003) recently proposed the mechanisms concerning 
PPARγ ligand-induced apoptosis would be occurring via a) perturbation 
of mitochondrial membrane permeability; b) binding of death receptor to 
its ligand; and c) phosphatidylinositol-3-kinase (PI3)-serine/threonine 
kinase (Akt)-apoptosis protease activating factor-1 (Apaf-1) system 
(down-regulation of survival signaling pathway) (Figure 1.4).  
 
 
1.7.1 Mitochondrial-dependent apoptosis 
 
 PPARγ ligands mainly induce apoptosis via perturbation of inner 
mitochondria membrane permeability (Yoshida et al., 2003). This 
mitochondrial-dependent apoptosis was termed intrinsic apoptosis where 
signals from various stimuli disturb the membrane permeability of the 
mitochondria and subsequently release the apoptogenic factor such as 
cytochrome c into the cytoplasm (Yoshida et al., 2003). During intrinsic 
apoptosis, anti-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2) and 
the pro-apoptotic protein such as Bcl-2 associated X protein (Bax) are 
induced to oligomerise and migrate from the cytoplasm to the 
mitochondria escort by various BH3-Only-Protrein (Debatin, 2004). Once 
the protein is inserted into the outer mitochondria membrane, it induces 
cytochrome c release by the creation or alteration of the mitochondria 
membrane pores (Debatin, 2004).  
 
In the cytoplasm, cytochrome c combines with Apaf-1 and pro-
caspase-9 to form a complex termed apoptosome, in the presence of 
adenosine 5’-triphosphate (ATP) to activate caspase-9 (Figure 1.5) 
(Roberts, 2000; Gewies, 2003; Debatin, 2004). Caspase-9 subsequently 
activates downstream executor caspases such as caspase-3, -6 and -7 
(Roberts, 2000). Activation of caspase-3 and the subsequent degradative 
events are probably triggered to initiate the apoptosis (Roberts, 2000; 
Yoshida et al., 2003; Debatin, 2004). In most PPARγ ligands induced 
apoptosis cases, caspase-3 is the final molecule where activation of 
caspase-3 will then causes DNA fragmentation (Yoshida et al., 2003).  
 
However, the mitochondrial pathway must not always associated 
with caspase activation (Debatin, 2004). The mechanism varies 
depending on the release of apoptogenic factor such as cytochrome c, 
Smac/Diablo or apoptosis inducing factor (AIF) (Figure 1.5) (Debatin, 
2004). The release of cytochrome c triggers caspase-9 activation through 
the formation of cytochrome c/Apaf-1/caspase-9 in the presence of ATP 
to form an active apoptosome complex as described above (Roberts, 
2000; Gewies, 2003; Debatin, 2004). Thus, the release of cytochrome c 
from mitochondria always reflects the mitochondrial→caspase-
9→executor caspase activation→apoptosis (Cai et al., 2002; Debatin, 
2004). The Smac/Diablo promotes caspase activation by neutralising the 
inhibitory effects of inhibitors of apoptosis proteins (IAPs) and this may 
also imply the same caspase activation pathway (Debatin, 2004). 
 
However, AIF causes DNA condensation or initiate apoptosis without 
activating any caspases (Debatin, 2004). 
 
 
1.7.1.1 Caspase activation in apoptosis  
 
Caspase(s) with the generic name c denotes a cysteine protease 
and aspase refers to the aspartate specific cleaving ability of these 
enzymes (Gewies, 2003). The individual members are then numbered 
according to their chronological order of publication (Robert, 2000). 
Caspase activation is recently demonstrated as central importance 
(hallmark) in the apoptosis signaling network as well as DNA 
fragmentation, which is activated in most cases of apoptotic cell death 
(Roberts, 2000; Gewies, 2003; Debatin, 2004). To date, 14 different 
members of the caspase have been described in mammals with 
caspase-11 and -12 only identified in mouse (Gewies, 2003). In broad 
terms, there are two groups of caspases; initiator caspase (such as -2, -
8, -9, and -10) and executor caspase (such as -3, -6 and -7) (Table 1.1) 
(Roberts, 2000; Gewies, 2003; Debatin, 2004).  
 
In the cell, caspases are synthesised as inactive zymogens. The 
inactive form of initiator caspase (e.g caspase-8) has longer domain than 
inactive form of executor caspase (e.g caspase-3) (Figure 1.6 A) 
(Gewies, 2003). The inactive form of caspase is so-called pro-caspase 
which at the N-terminus carry a pro-domain followed by a large and a 
 
small subunit. The large and the small subunits are sometimes separated 
by a linker peptide. Upon maturation, the pro-caspase is proteolytically 
processed between the large and small subunit where the domain is 
removed resulting in forming a heterotetramer consisting of two small 
and two large subunits. The heterotetramer is an active form of caspase. 
The disappearance of pro-caspase bands in Western blot analysis 
reflects processing of the zymogen to generate the active form of the 
specific caspase (Gewies, 2003; Cheah and Azimahtol, 2004). After the 
initiator pro-caspase is cleaved and activated, it subsequently actives the 
corresponding downstream executor pro-caspase molecules to become 
active caspase which in turn initiating the apoptosis (Figure 1.6 B) 
(Gewies, 2003). 
 
 The expression level of individual caspase may have an impact on 
their overall activity, since deficient expression level may simply impair 
caspase activation (Debatin, 2004). For example, MCF-7 breast 
carcinoma cells completely lack caspase-3 expression due to a frame 
shift mutation within exon 3 of the caspase-3 gene (Janicke et al., 1998). 
These cells can be sensitised to treatment with cytotoxic drugs by 
transfection of pro-caspase-3. Alternatively, caspase-8 expression was 
found to be frequently inactivated by hypermethylation of regulatory 
sequences of the caspase-8 gene in a number of different tumor cells 
derived from neuroblastoma, malignant brain tumors, Ewing tumors and 
small-cell lung carcinoma (Teitz et al., 2000; Fulda et al., 2001). 
Importantly, restoration of caspase-8 expression by gene transfer or 
 
demethylation treatment sensitised resistant tumor cells to death 
receptor-induced or drug-induced apoptosis (Fulda et al., 2001). In 
contrast, gene knockout experiments targeting caspase-9 and -3 resulted 
in mortality as a result of severe defects in brain development (Kuida, 
1998). Moreover, caspase-8-deficient embryos died after day 12 
(Varfolomeev, 1998). This and the observation indicating that cell lines 
derived from such knockout experiments are resistant to distinct 
apoptosis stimuli underlines the importance of caspases as pro-apoptotic 
mediator (Gewies, 2003). Indeed, it has been recognised that caspases 
play an important role in the apoptotic signaling machinery (Earnshaw, 
1999). 
 
 Given the important role of caspases as the final effectors 
molecule of apoptosis, the ability of anti-cancer agents such as PPARγ 
ligands to trigger caspase activation appears to be a critical determinant 
of sensitivity or resistance to cytotoxic therapies (Debatin, 2004). Indeed, 
caspases are useful biomarkers for apoptosis, as outlined below 
(Roberts, 2000). As a consequence, determination of caspase activation 
in various forms of cell death including PPARγ ligand-induced apoptosis 
may be an important factor in cancer chemotherapies (Debatin, 2004). 
 
 
 
 
 
1.7.2 Death receptor-ligand apoptosis 
 
 The death receptor-ligand system is so called extrinsic apoptosis 
because the apoptosis signal is initiated by the death receptor at cell 
surface (Goke et al., 2000; Gewies, 2003; Debatin, 2004). The death 
receptor belongs to the TNF gene superfamily and generally has several 
functions other than initiating apoptosis (Debatin, 2004). The best-
characterised death receptors are CD95 (or Fas), TNF receptor-1 (TNF-
R1) and TRAIL receptor (Goke et al., 2000; Roberts, 2000). The PPARγ 
ligand-induced death receptor apoptosis is at all times associated with 
the TNF receptor family (Goke et al., 2000).  
 
 
1.7.2.1 Signaling by CD95/Fas  
 
According to Ashkenazi and Dixit (1998), there are three main 
roles of CD95 signaling:  
 
1. mediate killing of cells by T-cells e.g. CTL-mediated killing of virus-
infected cells; 
2. mediate deletion of activated T-cells at the end of an immune 
response; 
3. mediate destruction of inflammatory and immune cells in immune-
privileged sites. 
 
 
